Retatrutide (GLP-3) and Fatty Liver Disease: What the Data Shows

Direct Answer

A Phase 2 substudy published in the peer-reviewed journal Nature Medicine found retatrutide reduced liver fat by approximately 82% to 86% at the highest dose over 48 weeks, using MRI-based imaging, with roughly 85 to 93% of participants who had fatty liver disease at baseline achieving normal liver fat levels by the end of the study. This is described as the largest liver fat reduction recorded for any pharmaceutical agent to date.

Why This Result Is Genuinely Distinctive

This effect is specifically driven by retatrutide's glucagon receptor activity, the third receptor target that distinguishes it from semaglutide and tirzepatide. Glucagon receptor activation directly signals liver cells to burn their own stored fat, a mechanism neither single-target GLP-1 medications nor dual GLP-1/GIP medications share to the same degree.

Why This Matters Beyond Weight Loss

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD, with its more severe inflammatory form MASH, formerly NASH) affects roughly one in three adults and currently has very few approved treatment options. Eli Lilly has included MASLD as a specific target indication in its Phase 3 program, with a dedicated liver disease trial expected to report results later in 2026.

What's Still Genuinely Unknown

This Phase 2 data used imaging (MRI-based fat measurement) rather than liver biopsy, the more definitive diagnostic standard. Phase 3 biopsy-based data is still needed to confirm these results translate into meaningful reductions in liver inflammation and fibrosis, not just fat content. It's also currently unknown whether liver fat reaccumulates after stopping treatment, the same open question covered on our discontinuation and weight regain page.

Bottom Line

Retatrutide's liver fat data is genuinely remarkable and well-published, but it remains Phase 2, imaging-based evidence, not yet confirmed by Phase 3 biopsy data or long-term outcome studies. This is a real, promising signal, not yet a settled, complete picture.

References

• Harrison SA, et al. Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease. Nature Medicine (2024)

Related Resources

• How Does Retatrutide (GLP-3) Work? Mechanism of Action Explained
• Fatty Liver Disease

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Track retatrutide alongside every other GLP-1 medication on DietApp.com.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. Retatrutide is investigational and not FDA-approved. This article is for general informational purposes and is not medical advice.